ダウンロード数: 347
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
1061186X.2012.716848.pdf | 294.73 kB | Adobe PDF | 見る/開く |
タイトル: | Controlling the kinetics of interferon transgene expression for improved gene therapy. |
著者: | Watcharanurak, Kanitta Nishikawa, Makiya Takahashi, Yuki https://orcid.org/0000-0002-8772-2772 (unconfirmed) Takakura, Yoshinobu https://orcid.org/0000-0002-7359-2647 (unconfirmed) |
著者名の別形: | 高橋, 有己 高倉, 喜信 |
キーワード: | Non-viral vector plasmid DNA CpG motifs plasmid backbone promoter enhancer |
発行日: | Nov-2012 |
出版者: | Informa Healthcare |
誌名: | Journal of drug targeting |
巻: | 20 |
号: | 9 |
開始ページ: | 764 |
終了ページ: | 769 |
抄録: | Interferon (IFN) gene based therapy has been studied for the treatment of many diseases such as viral infections, cancer and allergic diseases. Non-viral vectors, like plasmid DNA, are promising ways for delivering IFN genes, because of their low immunogenicity and toxicity compared with viral vectors. Potent therapeutic effects of IFN gene transfer will depend on the level and duration of transgene expression after in vivo administration. Therefore, controlling the kinetics of transgene expression of IFNs is a rational approach for improved gene therapy. The design and optimization of plasmid vectors, as well as their route/method of administration, is the key to obtaining high and persistent transgene expression. In this review, we aim to present experimental evidence about the relationships among the properties of plasmid vectors expressing IFNs, the kinetics of transgene expression, and therapeutic effects as well as safety issues. |
著作権等: | © 2012 Informa UK, Ltd. この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。 This is not the published version. Please cite only the published version. |
URI: | http://hdl.handle.net/2433/182930 |
DOI(出版社版): | 10.3109/1061186X.2012.716848 |
PubMed ID: | 22994266 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。